RGSH 4KAlternative Names: Autologous cancer vaccine - Regeneus
Latest Information Update: 19 Jun 2015
At a glance
- Originator Regeneus ltd
- Class Adjuvants; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 22 May 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in Australia (Intradermal)